FDA Clears Dexcom G7 15 Day, Marking the Longest-Lasting CGM System

The FDA cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes, making it the longest-lasting CGM system for patients.¹

The G7 15 Day system furthers the performance of Dexcom CGM | Image credit: Dulin | stock.adobe.com

“Dexcom G7 15 Day makes managing diabetes even easier with its extended wear and greater accuracy,” said Satish Garg, MD, from the Barbara David Center for Diabetes at the University of Colorado School of Medicine, in a news release. “Data recently released during the 18th international Advanced Technologies and Treatments for Diabetes (ATTD) conference in Amsterdam support that G7 15 Day is the most accurate CGM for adults.”¹

The G7 15 Day system furthers the performance of Dexcom CGM, which has been clinically proven to lower hemoglobin A1c (HbA1c) levels, reduce hyper- and hypoglycemia, and increase time in range for patients.^2,3 In addition to those features, the Dexcom G7 15 Day system has 15.5 days of wear, best-in-class accuracy with an overall mean absolute relative difference (MARD) of 8%, and easier glucose management with fewer monthly sensors and reduced waste.¹

Data released at the 2025 ATTD conference highlighted the MARD of 8%, making it the most accurate CGM system. Additionally, data from the Dexcom State of Type 2 report show that 52% of health care providers ranked access to CGM and education as having the potential to help individuals with type 2 diabetes manage their condition in the next 10 years, compared with 38% who cited better or more effective medications.⁴ These data emphasize the importance of providing education for patients using CGM devices, which pharmacists are well-positioned to do.

Furthermore, half of all health care providers surveyed felt that CGM should be the standard of care for individuals with type 2 diabetes, regardless of whether they use insulin to manage their condition. Of those surveyed, 96% agreed that those using multiple daily injections of insulin should receive a CGM, and 86% agreed that those relying on basal insulin should be offered a CGM.⁴

Despite these encouraging findings, there are still significant barriers to access, including funding constraints (35%) and narrow inclusion criteria (20%), which health care providers saw as primary barriers, according to the survey. Additionally, about 22% of health care providers believe that increasing education for individuals with type 2 diabetes could drive higher CGM usage.⁴

“With policymakers increasingly focused on digital transformation in health care, now is the time to push for greater investment in CGM technology as a core component of type 2 [diabetes] management,” said Adrian Gut, senior director of international access, advocacy, and value at Dexcom, in a news release. “Enhancing CGM accessibility is crucial to tackling the type 2 crisis. By ensuring equitable access to this life-changing technology, we can empower people with type 2 to take control of their diabetes management, improve their quality of life, and reduce complications.”⁴

The now-approved Dexcom G7 15 Day system furthers the significant progress made in the diabetes technology space. Like the Dexcom G7, the 15 Day system is the only waterproof CGM available. The sensor can be connected directly to users’ Apple Watches, and it provides simplified meal logging and medication logging, as well as the ability to remotely share glucose numbers with caregivers.¹

“By listening to the needs of our users, we’re proud to offer the longest-lasting wearable and most accurate CGM, giving people the knowledge to better control their diabetes with our best-in-class technology,” said Jake Leach, executive vice president and chief operating officer at Dexcom, in the news release.¹

REFERENCES

1. Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System. News release. Dexcom. April 10, 2025. Accessed April 10, 2025. https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx

2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections. JAMA. 2017;217(4):271-278. doi:10.1001/jama.2016.19975

3. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365-374. doi:10.7326/M16-2855

4. Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care. News release. Dexcom. March 19, 2025. Accessed April 10, 2025. https://investors.dexcom.com/news/news-details/2025/Dexcom-Report-Unveiled-at-ATTD-2025-Reveals-HCPs-Favour-Tech-Over-Medication-for-Future-of-Type-2-Care/default.aspx